Fulvestrant

Chemical formula: C₃₂H₄₇F₅O₃S Molecular mass: 606.78 g/mol PubChem compound: 17756771

Therapeutic indications

Fulvestrant is indicated for:

Locally advanced or metastatic hormone receptor (HR)-positive breast cancer in postmenopausal women

Population group: women, only adults (18 years old or older)

Fulvestrant is indicated:

as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:
- not previously treated with endocrine therapy, or
- with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.
in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

500 mg once monthly

Contraindications

Fulvestrant is contraindicated in the following cases:

Pregnancy

Lactation

Severe hepatic impairment

Hepatic failure stage IV

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.